Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine

Por Tang, Michele W., Rhee, Soo-Yon, Bertagnolio, Silvia, Ford, Nathan, Holmes, Susan, Sigaloff, Kim C., Hamers, Raph L., de Wit, Tobias F. Rinke, Fleury, Herve J., Kanki, Phyllis J., Ruxrungtham, Kiat, Hawkins, Claudia A., Wallis, Carole L., Stevens, Wendy, van Zyl, Gert U., Manosuthi, Weerawat, Hosseinipour, Mina C., Ngo-Giang-Huong, Nicole, Belec, Laurent, Peeters, Martine, Aghokeng, Avelin, Bunupuradah, Torsak, Burda, Sherri, Cane, Patricia, Cappelli, Giulia, Charpentier, Charlotte, Dagnra, Anoumou Y., Deshpande, Alaka K., El-Katib, Ziad, Eshleman, Susan H., Fokam, Joseph, Gody, Jean-Chrysostome, Katzenstein, David, Koyalta, Donato D., Kumwenda, Johnstone J., Lallemant, Marc, Lynen, Lutgarde, Marconi, Vincent C., Margot, Nicolas A., Moussa, Sandrine, Ndung'u, Thumbi, Nyambi, Phillipe N., Orrell, Catherine, Schapiro, Jonathan M., Schuurman, Rob, Sirivichayakul, Sunee, Smith, Davey, Zolfo, Maria, Jordan, Michael R., Shafer, Robert W.
Publicado em 2013